To further investigate the clinical implications of JAK2 and RUNX1 mutation, clinical and laboratory data were analyzed including age, gender, diagnosis, cytogenetics, percentage of bone marrow (BM) blast, absolute neutrophil count (ANC), hemoglobin (Hb), PLT and myelofibrosis (MF) status with Gomori staining positive (++~++++). The gene discussed is GSTM1; the disease is myelofibrosis.